Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085591 · Präparat HOS-083163
An additive effect on QT interval prolongation between Fareston and the following drugs and other
medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an
increased risk of ventricular arrhythmias, including Torsade de pointes. Therefore co-administration
of Fareston with any of the following medicinal products is contraindicated (see also section 4.3):
- antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)
- antiarrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)
- neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)
- certain antimicrobials agents (moxifloxacin, erythromycin IV, pentamidine, antimalarials
particularly halofantrine)
- certain antihistaminics (terfenadine, astemizole, mizolastine)
- others (cisapride, vincamine IV, bepridil, diphemanil).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) sotalol (HOS-085597) cisapride (HOS-085610) bepridil (HOS-085612) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) hydroquinidine (HOS-085594) sultopride (HOS-085603) lead (HOS-085592) disopyramide (HOS-085595) diphemanil (HOS-085613) pimozide (HOS-085600) erythromycin (HOS-084514) moxifloxacin (HOS-085604) astemizole (HOS-085608) pentamidine (HOS-085605) haloperidol (HOS-085602) amiodarone (HOS-085596) terfenadine (HOS-085607) vincamine (HOS-085611) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 9429395d1b572fb000ebac0968a84f8f195781287110169960c945b4772df6c6 · Zeichen 0–900 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) methylergonovine (HOS-086155) propafenone (HOS-084530) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 13
HOS-086202 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and
quinidine quinidine and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage db989a5b246ebda2c8effcb5a867688ba67111b2e2655b4b99403e29644def39 · Zeichen 13636–13987 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 45
HOS-086412 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and
quinidine is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 7be5a56d7eb28c6b0b362a7de5830a5d2ee65bd16f89e27afb151c7f671bb104 · Zeichen 13898–14249 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12–13
HOS-108863 · Präparat HOS-093083
12
CYP3A4 inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concomitant administration of
Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious
adverse reactions may be
increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if
inhibition by lopinavir/ritonavir. available, is recommended in case
The increased digoxin level may of co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra
in patients taking digoxin as the
acute inhibitory effect of ritonavir
on P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already
taking Kaletra is likely to result in
lower than expected increases of
digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine Quinidine: therapeutic drug concentration
Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of
may lead to a decreased exposure virological response.
of lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) clarithromycin (HOS-084517) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a6dc58dcb1aed961671098b7774afc6ab5284838d7c3becb73533d81f884e22 · Zeichen 9077–14069 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-109006 · Präparat HOS-093083
49
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of arrhythmias
or other serious adverse reactions
may be increased.
Digoxin Digoxin: Caution is warranted and therapeutic
Plasma concentrations may be drug monitoring of digoxin
increased due to P-glycoprotein concentrations, if available, is
inhibition by lopinavir/ritonavir. recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should be
induction develops. used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on P-gp
is expected to significantly increase
digoxin levels. Initiation of digoxin
in patients already taking Kaletra is
likely to result in lower than expected
increases of digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic
Lidocaine, and Quinidine: drug concentration monitoring is
Quinidine Concentrations may be increased recommended when available.
when co-administered with
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4). Caution
lopinavir/ritonavir. should be exercised in administering
clarithromycin with Kaletra to
patients with impaired hepatic or
renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the abemaciclib
SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead to
Serum concentrations of serious adverse events including
apalutamide may be increased due seizure due to higher apalutamide
to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage e2bfc1f119ab72d4142e3587fc0d81da448b5ce69a5003d6154afba7723f33c1 · Zeichen 9850–14882 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 84–85
HOS-109080 · Präparat HOS-093083
84
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of concomitantly administered with
CYP3A4 inhibition by Kaletra.
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious adverse
reactions may be increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if available,
inhibition by lopinavir/ritonavir. is recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on
P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already taking
Kaletra is likely to result in lower
than expected increases of digoxin
concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine: therapeutic drug concentration
Quinidine Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) clarithromycin (HOS-084517) fentanyl (HOS-086196) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 441e910c1e6908f1a8725254649dcb0f97fdc57cf122c18523aa47225be733b2 · Zeichen 9035–13902 im Abschnitt
Wechselwirkungen · Axura
Axura 10 mg film-coated tablets Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Axura 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-109260 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Axura
Axura 5 mg/pump actuation, oral solution · Abschnitt 4.5 · PDF-Seite 15
HOS-109291 · Präparat HOS-093165
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:43:00Z · SHA-256 f6f4d5233129ccc09d7b126c13573858c875ee45f87e7bb2987c68026bf63a30 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Gegenanzeigen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-109425 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) quinidine (HOS-085593) ergot alkaloids (HOS-108807) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92d039d4c373d2ccbb0905dc4377f6a8efd63303319839f8da1593b24c1c81cc · Zeichen 515–724 im Abschnitt
Gegenanzeigen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 36
HOS-109524 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration
phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 392392b9fe6da7258d9d0da5625b43e73df89387373d420d8ae08c8a730299d2 · Zeichen 515–979 im Abschnitt
Gegenanzeigen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 69
HOS-109587 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 52e206f10d0171fc7c859121398e23adfe815eb2cdb7b4fd04fb205bc3c3bde3 · Zeichen 515–854 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-109439 · Präparat HOS-093201
Voriconazole should be administered with caution in patients with concomitant medication that is known to
prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations
of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide
and ivabradine), coadministration is contraindicated (see below and section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) quinidine (HOS-085593) ivabradine (HOS-109426) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 884433aeccd3779ff59eb9cfe0e82b6516ccb1f376501034a4cd49f4a6361bfd · Zeichen 811–1209 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-109443 · Präparat HOS-093201
10
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7a8effc9a992647295e4846d1245734c400d850ebf1025fae94741d36bf5f346 · Zeichen 3549–4872 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 41
HOS-109531 · Präparat HOS-093201
Voriconazole should be administered with caution in patients with concomitant medication that is known to
prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations
of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide
and ivabradine), coadministration is contraindicated (see below and section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) quinidine (HOS-085593) ivabradine (HOS-109426) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 884433aeccd3779ff59eb9cfe0e82b6516ccb1f376501034a4cd49f4a6361bfd · Zeichen 811–1209 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42
HOS-109534 · Präparat HOS-093201
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUC 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUC 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax 15%
substrate] Voriconazole AUC 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUC ↔ No dose adjustment
[increases gastric pH]
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 534b27e000563107a8bd6c73d67131e3dbf51bbeeb2ec364adce0f84e9ccd348 · Zeichen 2117–4967 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 74
HOS-109595 · Präparat HOS-093201
Voriconazole should be administered with caution in patients with concomitant medication that is known to
prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations
of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide
and ivabradine), coadministration is contraindicated (see below and section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) quinidine (HOS-085593) ivabradine (HOS-109426) pimozide (HOS-085600)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 884433aeccd3779ff59eb9cfe0e82b6516ccb1f376501034a4cd49f4a6361bfd · Zeichen 811–1209 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 74–75
HOS-109599 · Präparat HOS-093201
74
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage ef4da431d6b5c0862699116f23a91056f1de4b33b7098a7a541240ab4f2f9841 · Zeichen 3706–4888 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-110226 · Präparat HOS-093339
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold,
respectively, indicating an inhibition of the CYP3A4 by imatinib. Therefore, caution is recommended
when administering Glivec with CYP3A4 substrates with a narrow therapeutic window (e.g.
cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil,
terfenadine, bortezomib, docetaxel and quinidine). Glivec may increase plasma concentration of other
CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers,
certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) simvastatin (HOS-086158) quinidine (HOS-085593) calcium (HOS-085615) docetaxel (HOS-084505) tacrolimus (HOS-085202) bortezomib (HOS-110227) pimozide (HOS-085600) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 90b6daf3cde987b8bbe424a8160367717eb0bce2aefbeba57f482ac99a1a5df9 · Zeichen 1905–2538 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.